Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Long Acting Opioid Prescriptions Increase Risk of Unintentional Drug Overdose, According to JAMA
  • USA - English


News provided by

Waismann Method

Feb 26, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Waismann Method
Waismann Method

Beverly Hills, California (PRWEB) February 26, 2015 -- The Waismann Method Medical Group is calling on physicians to alter their opioid prescribing methods in light of new data that shows an increased overdose risk in patients who are prescribed long acting formulations. The results of the study data supports the belief, that long acting opioids should only be prescribed by experienced physicians who are able to safely manage these medications, in order to minimize risks while effectively treating the patients’ pain.

One of the most fundamental precepts of medicine is to ‘Do No Harm’. Yet, this study reveals that current opioid prescribing practices are failing patients. Lives are being lost that could be saved.

Post this

Published in the February 16th issue of JAMA, the study reviewed the unintentional overdose risk of patients who were prescribed long and short-acting opioids for pain. It was performed in response to the alarming escalation of opioid overdose deaths in the last 20 years, which correlates to the increase in prescription rates of opioids for pain patients. Specifically, the study measured the overdose risk associated with long-acting versus short-acting opioid formulations in 840,606 Veterans Administration patients between the years of 2000 and 2009.

The results clearly indicate that patients who were prescribed long-acting opioids were two and a half times more likely to suffer an accidental drug overdose than those who were prescribed short-acting formulations. Even more concerning is that the study showed that the risk of accidental drug overdose among long-acting opioid patients was highest within the first two weeks of starting an opioid regime. The risk of overdose during the first two weeks was five times higher than with short-acting opioid medications.

"One of the most fundamental precepts of medicine is to ‘Do No Harm’. Yet, this study clearly reveals that current opioid prescribing practices are failing patients and resulting in unintended overdose and in some cases even death," said Dr. Michael Lowenstein, Medical Director of Waismann Method. “Lives are being lost that could have been saved simply by educating patients and physicians regarding the side effects and risks associated with these drugs. There must be a fundamental shift in how physicians treat pain, and it requires that they also assess the risk of unintentional overdose before prescribing these powerful and dangerous medications.”

In agreement with the article’s prescribing recommendation, The Waismann Method® Medical Group is calling on physicians to avoid prescribing long-acting opioid medications whenever possible, to reduce the unnecessary drug overdose risk that they pose to patients. When long-acting opioids are required, it is advisable that short-acting opioids be prescribed for a reasonable amount of time before switching to a long-acting formula.

For more information about WAISMANN METHOD®, please visit http://www.opiates.com. For interviews with Dr. Michael H. Lowenstein please contact Clare Waismann at 310-205-0808 or send an email to info(at)opiates(dot)com

About Waismann Method® Treatment

Since the late 90s, Waismann Method ® has been recognized as one of the premier opiate treatment centers in the United States, specializing in rapid opiate detoxification and utilizing the most advanced medical techniques to treat opiate dependence. Located in Southern California, Waismann Method® offers a variety of programs from anesthesia assisted rapid detox to modified medical opiate detoxification methods in conjunction with our exclusive post care facility Domus Retreat Recovery Center.

Michael H. Lowenstein, M.D., Medical Director for Waismann Method®, is considered an international authority on opiate addiction with four board certifications and over two decades of experience as a pain specialist and opioid addiction expert. He is board-certified in Addiction Medicine, Pain Management and Anesthesiology. Most recently, Dr. Lowenstein completed a fellowship and earned board certification in Anti-aging, Restorative and Regenerative Medicine to enhance his understanding and treatment of the effects of opioid use on the brain and other body systems.

Accompanied by his colleague registered addiction specialist Clare Waismann, Dr. Lowenstein operates in an accredited hospital which offers specialized care for patients with specific medical and dependency needs. Doctors, therapists and staff work hand-in-hand with patients to create personalized treatment and aftercare plans designed to ensure a healthy and effective transition to a life without opiates. Waismann Method® patients achieve an extraordinarily high success rate and thousands of patients have been effectively treated using our methods. The professionals at Waismann Method® always put compassionate science and responsible care over blame and punishment. Find out more about the Waismann Method® at http://www.opiates.com

Clare Waismann, Waismann Method, http://www.opiates.com, +1 (310) 205-0808, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.